| Patent Number |
Title Of Patent |
Date Issued |
| RE39916 |
Compounds that modulate PPAR activity and methods for their preparation |
November 6, 2007 |
| This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating |
| 7250444 |
Pyrrole-based HMG-CoA reductase inhibitors |
July 31, 2007 |
| HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided. |
| 7244763 |
Compounds that modulate PPAR activity and methods of preparation |
July 17, 2007 |
| This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treati |
| 7109222 |
Compounds that modulate PPAR activity and methods of preparation |
September 19, 2006 |
| This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating |
| 7067538 |
MCP-1 receptor antagonists and methods of use thereof |
June 27, 2006 |
| The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists. |
| 6964983 |
Compounds that modulate PPAR activity and methods for their preparation |
November 15, 2005 |
| This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or |
| 6951848 |
Functionalized heterocycles as modulators of chemokine receptor function and methods of use ther |
October 4, 2005 |
| Disclosed are novel compounds having the formula ##STR1##or a physiologically acceptable salt, amide, ester or prodrug thereof. The compounds can be used to modulate (antagonize, agonize) chemokine receptor function. Also disclosed is a method for treating a patient having an inflamm |
| 6939875 |
Compounds that modulate PPAR activity and methods for their preparation |
September 6, 2005 |
| This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or |
| 6875780 |
Compounds that modulate PPAR activity and methods for their preparation |
April 5, 2005 |
| This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating o |
| 6867224 |
Compounds that modulate PPAR activity and methods of preparation |
March 15, 2005 |
| This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or |
| 6001866 |
Method for treating and preventing inflammation and atherosclerosis |
December 14, 1999 |
| This invention provides a method for treating or preventing inflammation or atherosclerosis in mammals comprising administering an effective amount of a 15-LO inhibitor of Formula I: ##STR1## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sup.2, R.sup.3, R.sup.4, and R.sup. |
| 5620997 |
Isothiazolones |
April 15, 1997 |
| Isothiazolones having the general structure ##STR1## where A is a monocyclic or bicyclic ring which may contain up to 3 heteroatoms selected from O, S, and N; R.sup.1 and R.sup.2 are substituent groups such as alkyl, alkoxy, hydroxy, nitro, cyano, amino, and carboxy; and R.sup.5 |
| 5593967 |
Cholecystokinin antagonists, their preparation and therapeutic use |
January 14, 1997 |
| Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for prev |
| 5331006 |
Amino acid analogs as CCK antagonists |
July 19, 1994 |
| Novel unnatural dipeptoids useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. The compounds are agents useful for pr |
| 5208224 |
Phosphorus containing compounds as antihypercholesterolemic and antiatherosclerotic agents |
May 4, 1993 |
| Novel phosphorus containing compounds are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in preventing the intestinal absorption of cholesterol and thus are useful in the treatment of hypercholesterolemia and atherosclerosis. |
| 5155127 |
N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and |
October 13, 1992 |
| Novel N-[substituted aryl]-N'-(substituted alkoxy)-urea and thiourea derivatives are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in preventing the intestinal absorption of cholesterol and thus are useful in the treatment |
| 5130426 |
Synthesis of bis (morpholinomethyl) derivatives of tricyclic bis (dioxopiperazines) |
July 14, 1992 |
| Bis(morpholinomethyl) derivatives of tricyclic bisdioxopyperzaines of the formula ##STR1## wherein R is H, ##STR2## R' is H, lower alkyl groups (straight or branched chain of 1 to 6 carbon atoms) and the processes for the syntheses thereof are provided. |
| 5118697 |
Cyclic beta-ketoamide ACAT inhibitors |
June 2, 1992 |
| Novel cyclic beta-ketoamides which contain an aryl moiety having utility as blood cholesterol lowering agents rendering them useful in the treatment of atherosclerosis. |
| 5116848 |
N-(((2,6-disubstituted)phenyl)-N-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic |
May 26, 1992 |
| Certain N-2,6-dialkyl- or N-2,6-dialkoxphenyl-N'-diarylalkylurea compounds are potent inhibitors of the enzyme acyl CoA:cholesterol acyltransferase (ACAT), and are thus useful agents for the treatment of hypercholesterolemia or atherosclerosis with urea and thiourea compounds. |
| 5030653 |
Antihyperlipidemic and antiatherosclerotic compounds and compositions |
July 9, 1991 |
| Certain N-2,6-dialkyl- or N-2,6-dialkoxyphenyl-N'-arylalkylurea compounds are potent inhibitors of the enzyme acyl CoA:cholesterol acyltransferase (ACAT), and are thus useful agents for the treatment of hypercholesterolemia or atherosclerosis. |
| 5015644 |
Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
May 14, 1991 |
| Certain substituted urea, thiourea, carbamate, and thiocarbamate compounds are potent inhibitors of the enzyme acyl-CoA: cholesterol acyltransferase and are thus useful agents for inhibiting the intestinal absorption of cholesterol, and for lowering blood plasma cholesterol. |
| 4999373 |
Antihyperlipidemic and antiatherosclerotic compounds and compositions |
March 12, 1991 |
| Certain N-2,6-dialkyl- or N-2,6-dialkoxyphenyl-N'-arylalkylurea compounds are potent inhibitors of the enzyme acyl CoA: cholesterol acyltransferase (ACAT), and are thus useful agents for the treatment of hypercholesterolemia or atherosclerosis. |
| 4994465 |
Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds |
February 19, 1991 |
| Certain trisubstituted urea compounds as potent inhibitors of the enzyme acyl-CoA:cholesterol acyltransferase, their method of manufacture, pharmaceutical compositions containing such compounds as well as methods of inhibiting the interstitial absorption of cholesterol and lowering b |
| 4948806 |
Antihyperlipidemic and antiatherosclerotic compounds and compositions |
August 14, 1990 |
| Certain N-2,6-dialkyl- or N-2,6-dialkoxyphenyl-N'-arylalkylurea compounds are potent inhibitors of the enzyme acyl CoA:cholesterol acyltransferase (ACAT), and are thus useful agents for the treatment of hypercholesterolemia or atherosclerosis. |
| 4923896 |
N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and |
May 8, 1990 |
| Novel N-[substituted aryl]-N'-(substituted alkoxy)-urea and thiourea derivatives are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in preventing the intestinal absorption of cholesterol and thus are useful in the treatment |
| 4868210 |
Antihyperlipidemic and antiatherosclerotic compounds and compositions |
September 19, 1989 |
| Certain N-2,6-dialkyl- or N-2,6-dialkoxyphenyl-N'-arylalkylurea compounds are potent inhibitors of the enzyme acyl CoA:cholesterol acyltransferase (ACAT), and are thus useful agents for the treatment of hypercholesterolemia or atherosclerosis. |
| 4837207 |
Diastereoisomers of n.sup.6 -endo-bicyclo[2.2.1]heptyladenosine as antihypertensives with select |
June 6, 1989 |
| (1R-endo) or (1S-endo)-N-bicyclo[2.2.1]heptyl adenosine and pharmaceutically acceptable acid addition salts having highly desirable antihypertensive properties and unexpected A.sub.1 and A.sub.2 receptor binding activity, processes for their manufacture and pharmaceutical composition |
| 4791103 |
2,N.sup.6 -disubstituted adenosines, derivatives and methods of use |
December 13, 1988 |
| Novel N.sup.6 -substituted adenosines having desirable ratio of affinities at A1 or A2 receptors and highly desirable central nervous system and cardiovascular activities, such as analgesic, antipsychotic, sedative, or antihypertensive as well as immunoinflammatory activity. |
| 4780464 |
(1,2,4)triazolo(4,3-a)quinoxaline-4-amines |
October 25, 1988 |
| A unique series of [1,2,4]triazolo[4,3-a] quinoxaline-4-amine derivatives which show excellent binding affinity at both the A.sub.1 and A.sub.2 adenosine receptor sites. The compounds are useful in treating depression, fatigue, and heart failure. Also disclosed are methods for preparing |
| 4683223 |
N.sub.6 -Benzopyrano-and benzothiopyrano adenosines and methods of use |
July 28, 1987 |
| N.sup.6 -Benzopyrano- and benzothiopyranoadenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system antiinflammatory and antihypertensive properties, processes for their manufacture and pharmaceutical compositions and methods for using |
| 4673670 |
N.sup.6 -acenaphthyl adenosines and analogs thereof |
June 16, 1987 |
| N.sup.6 -Acenaphthyl adenosines and analogs thereof and pharmaceutically acceptable acid addition salts having highly desirable blood pressure lowering properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are |
| 4663313 |
N.sup.6 -tricyclic adenosines for treating hypertension |
May 5, 1987 |
| N.sup.6 -Tricyclic adenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical composition and methods for using said compounds and compositions are describ |
| 4614732 |
N.sup.6 -acenaphthyl adenosines and analogs thereof |
September 30, 1986 |
| N.sup.6 -acenaphthyl adenosines and analogs thereof and pharmaceutically acceptable acid addition salts having highly desirable blood pressure lowering properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are |
| 4593019 |
N.sup.6 -tricyclic adenosines |
June 3, 1986 |
| N.sup.6 -Tricyclic adenosines and pharmaceutically acceptable acid addition salts having highly desirable central nervous system and cardiovascular properties, processes for their manufacture and pharmaceutical compositions and methods for using said compounds and compositions are de |
